Business · 18/10/2026

XellSmart Unveils Phase I Results of Off-the-Shelf Parkinson's Disease Cell Therapy

XellSmart, a South Korean and Chinese biotech company, has announced the completion of Phase II enrollment for its off-the-shelf Parkinson's Disease cell therapy, following the presentation of Phase I results at the International Congress of Parkinson's Disease. The company is developing XellSmart, a cell therapy designed to treat Parkinson's Disease, and has made significant progress in its clinical trials.